LONDON—A flurry of new cancer-drug data coming from a conference in Europe is offering fresh promise for immunotherapies—drugs that boost patients' immune systems—especially their prospects when combined with other immunotherapies and existing drugs. . A highlight from the closely watched conference, which kicked off in Madrid Friday, has been the encouraging trial results for immunotherapy drugs that release one specific brake on the immune system—acting on a protein called Programmed Death Receptor 1 (PD-1) or a related target...
  